IRIS
DE GIORGI, UGO FEDERICO FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.919
AS - Asia 4.853
EU - Europa 1.712
Continente sconosciuto - Info sul continente non disponibili 556
SA - Sud America 495
AF - Africa 60
OC - Oceania 1
Totale 12.596
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.134
HK - Hong Kong 2.196
SG - Singapore 1.757
IT - Italia 1.496
BR - Brasile 422
CN - Cina 360
CA - Canada 320
VN - Vietnam 189
BD - Bangladesh 146
CW - ???statistics.table.value.countryCode.CW??? 92
IN - India 87
CR - Costa Rica 82
GB - Regno Unito 78
GP - Guadalupe 76
PR - Porto Rico 57
SV - El Salvador 49
MX - Messico 46
JM - Giamaica 33
GT - Guatemala 30
HN - Honduras 30
AR - Argentina 25
TT - Trinidad e Tobago 21
IQ - Iraq 20
ZA - Sudafrica 18
DE - Germania 17
NI - Nicaragua 15
EC - Ecuador 14
NL - Olanda 14
TR - Turchia 14
SA - Arabia Saudita 13
RO - Romania 11
RU - Federazione Russa 11
UZ - Uzbekistan 11
CO - Colombia 10
PL - Polonia 10
UA - Ucraina 10
FR - Francia 9
PK - Pakistan 9
BB - Barbados 8
ES - Italia 8
ID - Indonesia 8
JP - Giappone 8
MA - Marocco 8
TN - Tunisia 8
EE - Estonia 7
CL - Cile 6
IE - Irlanda 6
LT - Lituania 6
UY - Uruguay 6
AT - Austria 5
DZ - Algeria 5
ET - Etiopia 5
KE - Kenya 5
VE - Venezuela 5
CZ - Repubblica Ceca 4
EG - Egitto 4
NP - Nepal 4
PY - Paraguay 4
AZ - Azerbaigian 3
BS - Bahamas 3
JO - Giordania 3
MD - Moldavia 3
OM - Oman 3
PH - Filippine 3
PS - Palestinian Territory 3
SE - Svezia 3
VC - Saint Vincent e Grenadine 3
AE - Emirati Arabi Uniti 2
BM - Bermuda 2
CG - Congo 2
DO - Repubblica Dominicana 2
FI - Finlandia 2
GH - Ghana 2
KG - Kirghizistan 2
KR - Corea 2
KZ - Kazakistan 2
LV - Lettonia 2
MY - Malesia 2
PT - Portogallo 2
AG - Antigua e Barbuda 1
AL - Albania 1
AU - Australia 1
BE - Belgio 1
BG - Bulgaria 1
CU - Cuba 1
CY - Cipro 1
GD - Grenada 1
GE - Georgia 1
GF - Guiana Francese 1
GR - Grecia 1
GY - Guiana 1
HT - Haiti 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
KY - Cayman, isole 1
LC - Santa Lucia 1
LY - Libia 1
MK - Macedonia 1
NO - Norvegia 1
Totale 12.124
Salva come PNG Salva come JPEG
Città #
Hong Kong 2.193
Council Bluffs 942
Ashburn 654
Milan 409
San Jose 300
Singapore 276
Santa Clara 159
Rome 120
Willemstad 91
Naples 78
Beijing 76
New York 75
North Bergen 73
Miano 70
Los Angeles 67
San José 67
Ho Chi Minh City 54
Hanoi 52
Montreal 47
San Salvador 45
Dallas 42
Mumbai 40
Bologna 32
Atlanta 31
São Paulo 31
Toronto 28
Turin 28
Guatemala City 27
Florence 26
Chicago 24
Mexico City 24
Palermo 24
San Juan 23
Figino 20
Orem 20
Kingston 19
Bari 18
Philadelphia 18
Tampa 17
Brooklyn 15
Managua 15
San Francisco 15
Buffalo 14
Calgary 14
Dhaka 14
Edmonton 14
Genoa 14
Vancouver 14
Da Nang 13
Houston 13
London 13
Petit-Bourg 13
Denver 12
Phoenix 12
Richmond 12
Tegucigalpa 12
Arecibo 11
Bar Harbor 11
Brescia 11
Las Vegas 11
Pointe-à-Pitre 11
San Pedro Sula 11
Cagliari 10
Rio de Janeiro 10
Venice 10
Warsaw 10
Washington 10
Charlotte 9
Memphis 9
Miami 9
San Pietro Vernotico 9
Tashkent 9
Winnipeg 9
Baghdad 8
Brasília 8
Chaguanas 8
Hamilton 8
Les Abymes 8
Queens 8
The Bronx 8
Biên Hòa 7
Boardman 7
Bridgetown 7
Capesterre-Belle-Eau 7
Catania 7
Frankfurt am Main 7
Le Gosier 7
New Delhi 7
Orlando 7
Porto Alegre 7
Québec 7
Seattle 7
Thái Nguyên 7
Tokyo 7
Verona 7
Ancona 6
Baie-Mahault 6
Fort Lauderdale 6
Goiânia 6
Indianapolis 6
Totale 6.930
Salva come PNG Salva come JPEG
Nome #
68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer 129
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 129
A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity 126
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. 118
Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. 100
Prevention and therapy of neutropenia in elderly patients 97
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer 97
Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey 96
Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis 96
68 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients 92
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 88
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial 88
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients 87
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial 87
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial 85
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial 85
PSMA expression: A potential ally for the pathologist in prostate cancer diagnosis 80
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial 80
Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer 79
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials 78
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial 76
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry 75
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study 74
[177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet? 73
Conditional survival of patients treated with first-line chemotherapy for metastatic urothelial cancer 72
Anticancer drug delivery with nanoparticles 72
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry 72
Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma 72
Adjuvant concomitant chemotherapy in pancreatic cancer. 71
PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis 71
A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study 70
International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer 68
18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases 68
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 67
A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization 67
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone 66
Salvage high-dose chemotherapy in female patients with relapsed/refractory germ cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT) 66
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. 66
A Phase II study of everolimus plus oral prednisone in patients with metastatic renal cell cancer 66
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 65
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 65
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 64
A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer 63
Multiple cycles of PBPC-supported high-dose carboplatin and paclitaxel following mobilization with epirubicin and cisplatin are feasible but ineffective in treating patients with advanced non-small cell lung cancer 62
Germ cell tumours of the testis 62
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination 61
[18F]fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy. 61
Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features 61
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy 61
Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy. 59
Real-world experience and clinical impact of drug-drug interactions in HR+/HER2- advanced breast cancer patients treated with abemaciclib plus endocrine therapy: the AB-ITALY study 59
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 59
Long-term follow-up of patients with poor prognosis germ cell tumor treated with early high-dose chemotherapy with hematopoietic progenitor cell support: a single-center experience 58
Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study 57
Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger 57
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial 57
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 57
Hydroxychloroquine as Prophylaxis for COVID-19: A Review 56
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 56
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: Results from the Italian national registry 56
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer 56
Ovarian Sertoli-Leydig cell tumor, endometrioid-like yolk sac tumor, and Y-chromosomal material 55
Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer 55
High-dose chemotherapy for adult-type ovarian granulosa cell tumors: a retrospective study of the European Society for Blood and Marrow Transplantation 54
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 54
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators 54
Global approach to hepatic metastases from colorectal cancer: indication and outcome of intra-arterial chemotherapy and other hepatic-directed treatments 53
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial 53
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 53
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer 52
Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies 52
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy 52
Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer 51
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 51
Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999 51
Cell-free DNA as a diagnostic marker for cancer: current insights 50
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/ HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial 50
Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone 49
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone 49
Dose intensification in hormone receptor–negative and/or human epidermal growth factor receptor 2–negative high-risk primary breast cancer. 49
Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial 49
Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: Results of an Italian multicentre study 48
High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer 48
The prognostic value of pain in castration-sensitive prostate cancer 47
Role of DNA repair machinery and p53 in the testicular germ cell cancer: A review 47
First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study 47
Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor? 46
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma 46
GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications 46
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib 46
Immunotherapy for prostate cancer: Where we are headed 45
Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study 45
Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience 45
Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology 45
Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors 44
First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party 44
Consider quality of life to improve quality of cancer guidelines 43
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 43
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? 43
Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. 43
Totale 6.458
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.586
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.586
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20252.898 0 0 0 0 0 0 315 6 1.345 704 213 315
2025/20263.510 635 795 274 197 129 126 353 188 251 328 103 131
2026/20276.188 444 877 971 3.249 647 0 0 0 0 0 0 0
Totale 12.596